The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The late phase of sepsis is characterized by an increased microbiological burden and death rate
Open accessAbstract
Introduction: Recent models capturing the pathophysiology of sepsis and ex-vivo data from patients are speculating about immunosuppression in the so-called late phase of sepsis. Clinical data regarding survival and microbiological burden are missing. The aim of this study was to determine the clinical significance of the 'late phase' of sepsis with respect to overall survival and occurrence of microbiological findings. Methods: In a retrospective trial, 16,041 patient charts from a university intensive care unit were screened, and 999 patients with severe sepsis or septic shock were identified. Three phases were established according to the mortality peaks which were separated by two distinct nadirs: phase I (days 1 to 5), phase II (days 6 to 15) and phase III (days 16 to 150). Patients were analyzed for outcome, SOFA scores, procalcitonin levels, antimicrobial treatment, dialysis, mechanical ventilation and results of blood cultures during their hospital stay. Results: Out of 999 enrolled patients, 308 died during the course of sepsis presenting a characteristic mortality rate (30.8%) with three distinct mortality peaks (at days 2, 7 and 17). Overall 36.7% of all deaths occurred in the early phase (phase I) and 63.3% during the later phases (phase II + III). In total 2,117 blood cultures were drawn. In phase I, 882 blood cultures were drawn, representing a sampling rate of 88% with a positive rate of 14.9%. In phase II, 461 samples were taken, indicating a sampling rate of 52% and a positive rate of 11.3%. Within phase III, 524 samples were obtained representing a sampling rate of 66% with a positive rate of 15.3%, which was significantly higher compared to the positive rate of phase II and similar to phase I. In particular, the rate of typically opportunistic bacteria increased significantly from 9% in phase I up to 18% in phase III. The same is true for Candida spp. (phase I 13%, phase III 30%). Conclusions: The later phase of sepsis is associated with a significant re-increase of positive blood culture results, especially regarding opportunistic bacteria and fungi. These observations warrant further studies focusing on the underlying mechanisms resulting in this outcome burden in the later phase of sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Early goal-directed therapy in the treatment of severe sepsis and septic shock
Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., & Tomlanovich, M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010307 · Cited by 10,743
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Bernard, G. R., Vincent, J.-L., Laterre, P.-F., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,132
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
The Pathophysiology and Treatment of Sepsis
Hotchkiss, R. S., & Karl, I. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021333 · Cited by 4,097
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationHotchkiss, R. S., Strasser, A., McDunn, J. E., & Swanson, P. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0901217 · Cited by 1,154
Sir Isaac Newton, sepsis, SIRS, and CARS
Bone, R. C. (1996) · Critical Care Medicine · doi:10.1097/00003246-199607000-00010 · Cited by 989
Novel strategies for the treatment of sepsis
Riedemann, N. C., Guo, R.-F., & Ward, P. A. (2003) · Nature Medicine · doi:10.1038/nm0503-517 · Cited by 773
Self-citationMeisel, C., Schefold, J. C., Pschowski, R., Baumann, T., Hetzger, K., Gregor, J., Weber-Carstens, S., Hasper, D., Keh, D., Zuckermann, H., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0363oc · Cited by 648
Abraham, E. (1998) · The Lancet · doi:10.1016/s0140-6736(00)80009-4 · Cited by 624
Abraham, E. H., Anzueto, A., Gutiérrez, G., Tessler, S., Pedro, G. S. S., Wunderink, R. G., Nogare, A. R. D., Nasraway, S. A., Berman, S., Cooney, R. N., et al. (1998) · PubMed · Cited by 622
Immunotherapy for Sepsis — A New Approach against an Ancient Foe
Hotchkiss, R. S., & Opal, S. (2010) · New England Journal of Medicine · doi:10.1056/nejmcibr1004371 · Cited by 367
Immunomodulatory therapies in sepsis
Kox, W. J., Volk, T., Kox, S. N., & Volk, H. D. (2000) · Intensive Care Medicine · doi:10.1007/s001340051129 · Cited by 256
Westh, H., Lisby, G., Breysse, F., Böddinghaus, B., Chomarat, M., Gant, V., Goglio, A., Raglio, A., Schuster, H., Stuber, F., et al. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02736.x · Cited by 228
EARLY ASSESSMENT OF LEUKOCYTE ALTERATIONS AT DIAGNOSIS OF SEPTIC SHOCK
Venet, F., Davin, F., Guignant, C., Larue, A., Cazalis, M.-A., Darbon, R., Allombert, C., Mougin, B., Malcus, C., Poitevin-Later, F., et al. (2010) · Shock · doi:10.1097/shk.0b013e3181dc0977 · Cited by 215
Nelson, S., Belknap, S. M., Carlson, R. W., Dale, D., DeBoisblanc, B., Farkas, S., Fotheringham, N., Ho, H., Marrie, T., Movahhed, H., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/515694 · Cited by 204
Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?
Netea, M. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00079-6 · Cited by 195
Kox, W. J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440250031004 · Cited by 160
The Lingering Consequences of Sepsis: A Hidden Public Health Disaster?
Angus, D. C. (2010) · JAMA · doi:10.1001/jama.2010.1546 · Cited by 136
Unraveling Severe Sepsis: Why Did OPTIMIST Fail and What's Next?
Angus, D. C., & Crowther, M. A. (2003) · JAMA · doi:10.1001/jama.290.2.256 · Cited by 39
Cited by
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772
Hotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J.-L. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.45 · Cited by 1,620
Self-citationImmunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70001-x · Cited by 1,442
Sepsis: pathophysiology and clinical management
Gotts, J. E., & Matthay, M. A. (2016) · BMJ · doi:10.1136/bmj.i1585 · Cited by 1,243
The immune system’s role in sepsis progression, resolution, and long-term outcome
Delano, M. J., & Ward, P. A. (2016) · Immunological Reviews · doi:10.1111/imr.12499 · Cited by 880
Metadata
- Authors
- Otto, G. P., Sossdorf, M., Claus, R. A., Rödel, J., Menge, K., Reinhart, K., Bauer, M., & Riedemann, N. C.
- Venue
- Critical Care
- Published
- 2011-07-28
- Volume
- 15
- Issue
- 4
- Pages
- R183-R183
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2160578994
- Cited by
- 434
- References
- 24
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.